Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Effect of Earlier Initiation of Inhaled Treprostinil (iTRE) on Long Term Outcomes in Patients with Pulmonary Arterial Hypertension (PAH)

Raymond Benza

S. K. Gotzkowsky

A. Jenkins

Lewis Rubin


  Sign in to add a review

Leave a Comment

Conference: 2012 International PHA Conference and Scientific Sessions

Release Date: 06.22.2012

Presentation Type: Abstracts

R Benza1; K Gotzkowsky2; A Jenkins2; L Rubin3

1. Allegheny General Hospital, Pittsburgh, PA
2. United Therapeutics Corp., Research Triangle Park, NC
3. UCSD Medical Center, San Diego, CA

PURPOSE: Current PAH treatment algorithms encourage a stepwise, add-on approach. At present, the ideal time to add-on prostacyclin therapy remains unknown. TRIUMPH-1 was a 12-week double blind (DB) trial of iTRE in patients stabilized on an oral background therapy with a long term open-label (OL) extension. This analysis compares efficacy outcomes up to 2 years with OL iTRE in patients originally assigned in DB to iTRE (iTRE/ iTRE) or PBO (PBO/ iTRE).

METHODS: 206 subjects (125 US, 81 Rest of World) participated in OL. Six minute walk distance (6MWD), quality of life (MLwHF), and NYHA functional class were assessed every 3 months. Exposure time for all patients was calculated based on time on active iTRE.

RESULTSMedian baseline 6MWD was 359 meters for 97 patients receiving iTRE/iTRE and 365 meters for 109 patients receiving PBO/iTRE. Marked improvements in 6MWD were noted in iTRE/ iTRE as compared with PBO/ iTRE, with median changes of 37, 38, 35 and 26 meters vs. 19, 25, 22, and 5 meters at 6, 12, 18, and 24 months respectively. After 18 and 24 months of therapy respectively, 45% and 38% iTRE/iTRE had improvements in 6MWD of >50m compared to 32% and 27% in PBO/iTRE. A greater frequency of improvement in components of MLwHF was also noted in iTRE/iTRE, as were decreases in functional class (FC) at 24 months compared to baseline (42% iTRE/iTRE vs. 30% PBO/iTRE).

CONCLUSIONS: PAH is a progressive disease often requiring multiple therapies. These data obtained in patients stabilized on an oral PAH medication suggest that the earlier addition of inhaled treprostinil provides long-term improvement in exercise capacity and QOL, while also demonstrating the potential outcome of delaying active therapy in placebo controlled trials.

FUNDING:  United Therapeutics Corp